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comparison was applied to compare entecavir with interferon and the combination of 
interferon and lamivudine. When compared with lamivudine, the combination of inter-
feron and lamivudine yielded the best efﬁ cacy which was about two times more likely to 
increase HBeAg seroconversion rate (OR = 2.38, 95% CI = 1.21–4.06) than entecavir 
(OR = 0.98, 95% CI = 0.56–1.44) and interferon (OR = 1.17, 95% CI = 0.44–2.24). In 
addition, when compared with either interferon or entecavir, interferon plus lamivudine 
was about two to three times more likely to enhance HBeAg seroconversion rate with the 
OR of 2.48 (95% CI = 1.05–4.92) or 2.71 (95% CI = 1.13–5.33), respectively. CONCLU-
SIONS: There was a signiﬁ cant increase in HBeAg seroconversion rate in patients with 
HBeAg positive CHB receiving the combination of interferon and lamivudine com-
pared with lamivudine, entecavir and interferon. 
PGI3
EFFECTIVENESS AND COST ANALYSIS OF PARENTERNAL REGIMEN IN 
CRITICAL ILLNESS PATIENTS OF POSTOPERATIVE: THREE-
COMPARTMENT BAG SYSTEM AND TRANDITIONAL SEPARATE BOTTLE 
SYSTEM
Hsieh HJ, Chan AL
Chi-Mei Medical Center, Tainan, Taiwan
OBJECTIVES: To evaluate clinical outcome and direct medical cost using Kabiven 
and traditional peripheral partenteral nutrition for postoperative patients in ICU. 
METHODS: This is a restrospective study. Medical records of postoperative patients 
in ICU were reviewed by clinical pharmacists from July 2008 to July 2009. The 
retrieved patients were divided into two groups, kabiven group (n = 49) and separate 
bottle group (SB) (n = 50). Patients, characteristics were evaluated and compared 
between two groups. The measured outcomes were the clinical effectiveness and direct 
medical costs. One way ANOVA were used for analysis. RESULTS: There were no 
statistically signiﬁ cance difference in patients, characteristics between two groups. 
Survival rate was higher in kabiven group than in SB group (40% vs. 31%, respec-
tively). The length of stay in hospital in kabiven group was longer than in SB group 
(47.51 ± 38.63 vs. 31.86 ± 21.99 days, respectively; P < 0.015). Total direct medical 
costs of survivors in kabiven group was more expensive than in SB group ($11,976.9 
vs. $9574.9, respectively). CONCLUSIONS: Although the direct medical cost of 
kabiven group were higher than SB group, use of kabiven is likely to improve mortality 
rate of postoperative patients in ICU. 
GASTROINTESTINAL DISORDERS – Cost Studies
PGI4
BUDGET IMPACT ANALYSIS OF ORAL ANTIVIRAL AGENTS FOR THE 
TREATMENT OF CHRONIC HPATITIS B IN SOUTH KOREA
Na JH, Lee EK
Sookmyung Women’s University, Yongsan-gu, Seoul, South Korea
OBJECTIVES: Heptatitis B is prevalent in South Korea and chronic hepatitis B (CHB) 
infection is an important public health issue due to its potential to evolve to cirrhosis, 
hepatocellular carcinoma. This study estimated the direct medical cost of CHB-related 
disease states in South Korea and compared the cost of South Korea with that of USA, 
Australia and China. It also aimed to analyze the impact of three therapeutic alterna-
tives for CHB by Budget Impact Analysis (BIA). METHODS: Dynamic budget impact 
analysis was conducted based on a Markov model for 5 years. Three treatment sce-
narios were selected as follows: ﬁ rst-line treatment of lamivudine, second-line combi-
nation treatment of lamivudine and adefovir on the development of drug resistance, 
ﬁ rst-line treatment of lamivudine, second-line treatment of entecavir 1.0 mg on the 
development of drug resistance, ﬁ rst-line treatment of entecavir 0.5 mg, second-line 
treatment of adefovir on the development of drug resistance, no treatment available. 
RESULTS: The BIA results of scenario A, B, C and no treatment were 75, 74.7, 85.9, 
and 48.1 billion Korean Won (KRW), respectively. The results were relatively insensi-
tive to the TP and sensitive to the number of treated patients based on sensitivity 
analyses. The costs of annual direct medical costs in South Korea were 23.2%~65.8%, 
16.2%~59.1%, and 75.8%~381.7% of the annual direct medical costs in the United 
States, Australia, and China. CONCLUSIONS: Scenario C (ﬁ rst-line treatment of 
entecavir 0.5 mg, second-line treatment of adefovir) was found to be 10.9~11.2 billion 
KRW more expensive than scenario A and B from payer’s perspective. In South Korea, 
the direct medical costs of CHB-related diseases are cheaper than the United States 
and Australia. It suggests that such factors as the difference of GNP (Gross National 
Product), health-care system and others contribute to the difference of the direct 
medical costs. 
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EVALUATION OF OCTREOTIDE COST AFTER PHARMACEUTICAL CARE 
IMPLEMENTATION AT SURGICAL WARD
Sawatpanit A
Department of Pharmacy, Roi-et Hospital, Muang, Thailand, Thailand
OBJECTIVES: Our objective was to compare cost saving before and after of pharma-
ceutical care implementation and Octreotide use evaluation at surgical ward. 
METHODS: This study was conducted during October 1, 2008 to April 30, 2009. The 
research instruments were octreotide use criteria with approval by surgical staffs. Phar-
macist reviewed and evaluated the medical chart in order to identify medication related 
problems by focusing on medication regimens. Medication related problems were clas-
siﬁ ed into three categories: inappropriate route, inappropriate duration and inappropri-
ate indication of administration. Cost saving was based on drug costs. The pre- and 
post-pharmaceutical care implementation and octreotide use evaluation results were 
compared and analyzed with descriptive retrospective statistics and paired t–test at 95 
% signiﬁ cant level. RESULTS: There were 302 patients received Octreotide. One 
hundred ninety-three patients (63.9%) were prescribed Octreotide appropriately. Medi-
cation related problems were found in 109 patients (36.1%). The most frequent prob-
lems were inappropriate duration (44.95%), inappropriate indication (34.86%) and 
inappropriate route of administration (20.18%). The cost of Octreotide use for inap-
propriate duration, inappropriate indication and inappropriate route of administration 
were signiﬁ cantly decreased after pharmaceutical care implementation 3,062,160 versus 
1,946,400 baht, 657,000 versus no money, and 919,800 versus 226,800 baht, respec-
tively (P < 0.005). The total cost of Octreotide use was 9,529,950 baht reducing to 
7,015,008 baht after pharmaceutical care implementation with statistically signiﬁ cant 
(P < 0.005). CONCLUSIONS: The implementation of pharmaceutical care and evalu-
ation of Octreotide use resulted in signiﬁ cant cost saving. The drug utilization 
program, consisting of deriving quality criteria for prescribing, structured order form 
and good cooperation between physicians and pharmacists with strong support of the 
therapeutics committee, was an effective strategic approach to promote rational drug 
use and develop Octreotide use guidelines. 
GASTROINTESTINAL DISORDERS – Patient-Reported Outcomes Studies
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THE EFFECT OF ANTIVIRAL THERAPY ON QUALITY OF LIFE IN 
CHRONIC HEPATITIS PATIENTS: A SYSTEMATIC REVIEW
Pansang S, Maphanta S
Naresuan University, Muang, Phitsanulok, Thailand
OBJECTIVES: Chronic viral hepatitis B and C are treated primarily with interferon 
(IFN) and/or nucleotide analogs e.g., ribavirin (RBV) which produced sustained viral 
response in more than 50% of treated patients. However, the combination may also 
cause numerous side effects that could reduce patients’ quality of life (QoL). To 
determine the effect of antiviral therapy on QoL of chronic hepatitis patients. 
METHODS: Key words were “Quality of life” AND “chronic hepatitis” AND “anti-
viral therapy,” “lamivudine,” “ribavirin,” “adefovir,” “entacavir,” “telbivudine” 
“tenofovir” and were searched from PubMed and EMBASE database. Study selection 
criteria were original articles in which patients received antivirals for chronic hepatitis 
B or C, and assessed QoL. The comparators were no treatment, placebo or at least 
one other antiviral. Studies that involved co-HIV infection were excluded. One inde-
pendent researcher reviewed titles and abstracts to determine relevance. Study design, 
dose, duration, baseline values, and QoL scores were extracted. RESULTS: Six studies 
met all the criteria. Four QoL instruments were used in those studies. SF 36 and 
HQLQ questionnaires were the most common. Patients who received peginterferonμ-
2a plus placebo reported better QoL than peginterferonμ-2a plus ribavirin during the 
treatment (week 2–48) in two RCTs. However, the results were less consistent and 
less prominent during the week of 72 and 96. The effect seemed to be non-dose related. 
One RCT showed that interferon μ plus ribavirin produced better QoL than untreated 
when measured with EQ 5D questionnaire, but it did not reach statistical signiﬁ cant. 
In similarly, peginterferone μ-2a plus ribavirin did not showed a signiﬁ cant better 
Fatigue severity scale at week 72 when compared with peginterferonμ-2a plus placebo. 
CONCLUSIONS: Antiviral therapy (interferon plus ribavirin) reduced QoL only 
during the treatment. Results seemed to be consistent across all four types of QoL 
questionnaires. 
GASTROINTESTINAL DISORDERS – Health Care Use & Policy Studies
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OBJECTIVES: This study was conducted to obtain information on current prescribing 
rates of antibiotics in diarrhea, a condition where misuse of antibiotics is common. 
In the absence of community-based databases on antibiotic use in developing countries 
recently a methodology was established for surveillance of antibiotic use at New Delhi 
by conducting ‘Exit Interviews’ of the patients. METHODS: Antibiotic use data was 
collected from public and private sector facilities from four residential localities 
around a tertiary care hospital where the antibiotic resistance work was being con-
ducted. All the 10 public sector facilities (eight primary and two secondary health 
cares) situated in the study area under Delhi government were enrolled. For private 
sector, 20 willing and cooperative general practitioners and specialists practicing in 
the chosen areas were selected. Patients after consultation with prescriber were asked 
if they had diarrhea but without blood. Patients with diarrhea were enrolled for exit 
interview and his/her prescription was monitored. Antibiotic use data was collected 
per month over 1 year (December 2007–November 2008). The percentage of patients 
receiving antibiotic and pattern of consumption for various antibiotics was analyzed. 
RESULTS: At public facilities 43% (171/398) and at private facilities 69% (76/110) 
of patients with diarrhea were prescribed at least one antibiotic. Main antibiotic class 
that was prescribed in public and private sector was ﬂ uoroquinolones (89% and 94%); 
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the second group in public sector was cephalosporins (4%) and in private sector were 
penicillins (3%). In private sector pediatricians prescribed antibiotics to 52% (17/33) 
of children with diarrhea and ﬂ uoroquinolone group was prescribed to all. At public 
facilities, main members from ﬂ uoroquinolones were norﬂ oxacin, followed by oﬂ oxa-
cin and ciproﬂ oxacin. At private clinics, it was oﬂ oxacin followed by ciproﬂ oxacin. 
Pediatricians mainly prescribed oﬂ oxacin, followed by norﬂ oxacin. CONCLUSIONS: 
This study clearly shows over-prescription and irrational use of antibiotics for treat-
ment of diarrhea that warrants interventional strategies. 
HEALTH CARE USE & POLICY STUDIES – Consumer Role in Health Care
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A STUDY EVALUATING PATTERN OF NON-PRESCRIPTION PURCHASE 
BY CONSUMERS FROM COMMUNITY PHARMACIES IN MALAYSIA
Ahmad Hassali MA, Shaﬁ e AA, Mohamad Yahaya AH
Universiti Sains Malaysia, Penang, Penang, Malaysia
OBJECTIVES: To analyze the pattern of non-prescription medicine purchase by 
consumer from community pharmacies in Malaysia. METHODS: A cross-sectional 
survey comprised a sample of 1799 community pharmacy consumers was conducted 
nationwide. A pharmacy “exit survey” was developed and administered to pharmacy 
consumers of randomly selected community pharmacies in order to collect information 
on the purchased nonprescription medicine(s) including its costs. In this study, the 
nonprescription medicine deﬁ nition was adopted from the Malaysian Poison Act 
1952. Data were analyzed using Kruskal–Wallis, Mann–Whitney, chi-square and 
Spearman correlation test in SPSS v15. RESULTS: A total of 2175 nonprescription 
medicines were purchased by consumers interviewed in 2 weeks study period. The 
total cost estimated for all item purchased was RM41,000 (USD13,000). About 
39.6% of the purchased items are listed under scheduled poison, 45.5% were unsched-
uled poison and 12.5% are those listed as traditional and complementary medicine. 
Medicine for alimentary tract and metabolism, musculo-skeletal system and respira-
tory system as categorized by Anatomical Therapeutic Coding were among the highest 
purchased medicine. Factors such as gender especially females, area of origin especially 
those from urban area, ethnicity especially chinese consumers and those earning high 
income level shows to have a signiﬁ cant inﬂ uence in the spending for non-prescription 
medicine purchasing. This study also showed purchasing for non-prescription medi-
cine signiﬁ cantly increased as aging. Consumers spent signiﬁ cantly more on non-
controlled medicine such as vitamins and herbal preparations compared to other 
categories of medicines (χ2 = 185.07, P < 0.001). CONCLUSIONS: The evaluation 
on pattern of nonprescription medicine purchasing in Malaysia reveals that consumers 
in Malaysia are able to spend money for buying medicines to treat minor ailments 
and practice of self-medication. The socio-demographic factors that associated with 
non-prescription medicine purchase will serve as useful information for policymakers 
and also the pharmaceutical industry for future development in rational medicine use 
education among consumers in the country. 
HEALTH CARE USE & POLICY STUDIES – Disease Management
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OBJECTIVES: Public awareness of rare diseases and access to orphan drugs is increas-
ing in China. The purpose of this study was to review the epidemics of rare diseases, 
the access to orphan drug treatments, and its related legislation in China. METHODS: 
A systematic literature review was performed based on published articles, government 
Websites, and some Internet search engines. The rare diseases, available orphan drug 
treatments, and related legislations in China were reviewed. Some comparisons related 
to these topics were discussed between China and developed countries like the United 
States. RESULTS: With conservative estimation, there are at least 10 million Chinese 
people living with rare diseases. The frequently mentioned rare diseases in China 
include osteogenesis imperfecta, neuromuscular diseases, Fabry disease, Gaucher 
disease, phenylketonurias, hemophilia A and B, lymphangioleiomyomatosis, albinism, 
and acromegaly. Patients with rare diseases in China generally lack the access to 
appropriate health care especially the orphan drug therapies. While we observed the 
signiﬁ cant impact of Orphan Drug Act on new drug developments and rare disease 
treatments in developed countries, there is little new orphan drug designated or devel-
oped in China. There are very few imported orphan drugs in the Chinese market. A 
grouping number of Chinese rare-disease organizations such as the China Albinism 
Association and the China-Dolls Care and Support Association are working with 
government on a new legislation about health care assesses and insurance policy for 
rare diseases. CONCLUSIONS: Public and governmental concerns about rare diseases 
have been boosted in China. Their available treatments and legislation in China are 
lagging far behind the United States, the European Union, Australia, Singapore, Japan, 
and South Korea. An effective public health insurance and public policy are needed for 
rare disease treatments and orphan drug developments. 
HEALTH CARE USE & POLICY STUDIES – Drug/Device/Diagnostic Use & 
Policy
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OBJECTIVES: Iran had one of the highest uses of Diphenoxylate in the world in 2008. 
About 1 billion tablets of Diphenoxylate 2.5 mg have been consumed during that year. 
In the last months of 2008 the ministry of health tried some policies to reduce the 
consumption. One was rationing in production the other was doubling the price of 
10 medicines which likely were abused including Diphenoxylate. This study tries to 
show the effectiveness of these two interventions by evaluating monthly consumption 
of Diphenoxylate during recent 5 years ended to March 2010. METHODS: Data were 
gathered from the distributors and wholesalers of this medicine from whole the 
country. These data were crosschecked with importation data in the ministry of health. 
We did a time trend analysis on tabulated data. RESULTS: There are some variations 
in monthly use of Diphenoxylate but the trend shows a signiﬁ cant decrease after the 
rationing in production. In 2009 the average consumption has reached to less than 
650 millions of tablet, four Deﬁ ned Daily Dose per 1000 Inhabitants per day which 
shows 36% decrease in comparison with the previous year. In second half of 2009 
and ﬁ rst 2 months of 2010 after the second intervention, there is no signiﬁ cant change 
in the trend. CONCLUSIONS: Although the high consumption of opiates in Iran is 
a multi factorial phenomena but this study shows; the ﬁ rst intervention has been able 
to control the abuse of Diphenoxylate due to the reduction of market supply and 
decrease in Diphenoxylate’s unofﬁ cial promotion. Considerable result wasn’t seen in 
the second approach. The user price of Diphenoxylate tablet in Iran is too cheap and 
doubling the price doesn’t work at all. A signiﬁ cant tax mark-up and increasing the 
price based on label use may affect on affordability of Diphenoxylate’s abuse. 
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THE ESSENTIAL MEDICINE SYSTEM IN CHINA: STRATEGIES AND 
CHALLENGES
Yang L
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OBJECTIVES: In the 1980s, China launched market-oriented reforms. Public hospi-
tals were encouraged to make their own incomes with the aim of mobilizing medical 
workers and improving hospital efﬁ ciency. Less government funding resulted in deﬁ -
cits for public health institutions, which forced hospitals to generate their own revenue 
by aggressively selling drugs, especially expensive drugs. There are challenges in poor 
drug access, drug procurement, rising drug costs and ﬁ nancial risk. In March 2009, 
China ﬁ nally unveiled its health care reform plan. The Chinese government announced 
it will institute an essential medicine system within 3 years to drive down prescription 
costs and quell public complaints of limited accessibility of medicines. This study is 
to describe the strategies to build the essential medicine system at the provincial level 
in China and challenges associated with promoting it. METHODS: Key actors, their 
power, views and interactions will be assessed using appropriate qualitative methods 
as these are best suited to understanding complexity, richness of material and motiva-
tions of actors, and using a policy analysis to know the key governance issues and 
underlying relationships affecting its success or failure. RESULTS: The system includes 
a list of essential medicines that would be produced and distributed under government 
control and supervision, and it should be used at all public health facilities at grass-
roots levels from 2009. The central government will set reference prices, based on 
which, provincial governments set the purchase prices of the drugs in their jurisdiction. 
Public medical and health facilities at the grassroots levels should sell the drugs at the 
purchase prices. These generally involve the transfer for a ﬁ xed fee from the local 
MOH to the health service center/post in exchange for the removal of retail mark up, 
which couldn’t offset the proﬁ t of selling drugs. CONCLUSIONS: The provider incen-
tive is very crucial for building an essential medicine system, which is dependent upon 
the reimbursement system. 
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RECOMMENDATIONS FOR A BIOLOGICS-SPECIFIC PRICING SYSTEM IN 
CHINA
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OBJECTIVES: The pricing system for chemical drugs is currently applied to biologics 
in China as no speciﬁ c pricing system for biologics exists yet in China. This practice 
does not fully reﬂ ect the characteristics of biologics and may potentially prevent the 
launch of biologics in China and discourage the development of biologics. The objec-
tive of this study is to explore adequate pricing mechanisms for biologics. METHODS: 
Both primary research (ﬁ eld research, expert interviews, surveys) and secondary 
research were conducted to determine the key determinants of the price of biologics 
and understand the complexity of R&D, manufacturing and distribution required for 
biologics. Statistical analyses were performed to assess the relationship of key deter-
minants and the price. Government and manufacturer behavior were modeled using 
game theory to demonstrate prerequisites of implementing ‘differential pricing’. 
RESULTS: A different pricing system is required for biologics given its unique char-
acteristics. Certain characteristics (including special clinical value, target-speciﬁ c R&D 
